Compare Endeavour Silver Corp (EXK) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Incyte Corporation — how do they compare? Endeavour Silver Corp trades at $10.64 (market cap $3.14B), while Incyte Corporation trades at $121.32 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 7.8× Endeavour Silver Corp's market cap, and Incyte Corporation is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals.
| EXK | INCY | |
|---|---|---|
Market Cap | $3.14B | $24.54B |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $129.93 |
52-Week Low | $5.31 | $81.61 |
Enterprise Value | $3.14B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $10.68, up 4.3% today, with a bullish technical outlook driven by moving averages and strong analyst sentiment. The company reported Q2 2026 earnings in line with estimates at $0.15 per share, with revenue growth and operational execution highlighted in recent news. Financials show improving trends, with 2026 revenue projected at $737 million and net income turning positive to $66 million, though 2025 saw a net loss of $119 million. A new $25 million credit facility was secured in August 2026, supporting liquidity.
The stock offers upside to the consensus price target of $15.50, with 79% of analysts rating it Buy. Key risks include volatile silver prices, execution challenges at new mines, and high valuation multiples like a P/E of 52.95. Positive catalysts include production ramp-ups and favorable metal price outlooks, but investors should monitor debt levels and commodity cycles.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
